Viatris Inc.
VTRS
Classement en actions
#1101
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Prix de l'action
$18.50
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$21.24B
Changement (1 jour)
1.29%
Changement (1 an)
78.01%
Pays
US
Échange Viatris Inc. (VTRS)
Catégorie
Healthcare
Ratio P/E pour Viatris Inc. (VTRS)
Ratio P/E au October 2026 TTM : -48.44
Selon les derniers rapports financiers et le cours de l'action de Viatris Inc., le ratio P/E actuel (TTM) est de -48.44. À la fin de l’année 2023, le P/E de l’entreprise était de 237.65.
Historique du ratio P/E pour Viatris Inc. de 2004 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | -48.44 | 106.76% |
| 2024 | -23.43 | -109.86% |
| 2023 | 237.65 | 3,561.56% |
| 2022 | 6.49 | -150.36% |
| 2021 | -12.89 | -23.37% |
| 2020 | -16.82 | -102.51% |
| 2019 | 670.00 | 1,568.83% |
| 2018 | 40.15 | 23.36% |
| 2017 | 32.55 | -21.33% |
| 2016 | 41.37 | 30.38% |
| 2015 | 31.73 | 31.72% |
| 2014 | 24.09 | -12.25% |
| 2013 | 27.45 | 54.35% |
| 2012 | 17.79 | 3.26% |
| 2011 | 17.22 | -13.30% |
| 2010 | 19.86 | -17.85% |
| 2009 | 24.18 | -257.52% |
| 2008 | -15.35 | 544.28% |
| 2007 | -2.38 | -108.19% |
| 2006 | 29.09 | 24.24% |
| 2005 | 23.41 | 28.15% |
| 2004 | 18.27 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -172.16% |
IN
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.